RxDoctor Payments Data

Joseph Scamardo, MD

Neurology · Nacogdoches, TXNPI 1639285489

Payments from drug & device makers

$2,477in general payments, 2019–2025

Across 189 payments — averaging $13.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$486
  • AbbVie$480
  • EMD Serono, Inc.$256
  • Biohaven Pharmaceutical Holding Company Ltd.$203
  • Amgen$187
  • Teva Pharmaceuticals USA, Inc.$184
  • plus $680 from 15 others

What the payments were for

  • Food & beverage$2,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,477 in reported general payments places this provider in the 45th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$55,631
Medicare patients
143
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant29$42,342
Aimovig AutoinjectorErenumab-Aooe47$34,959
RytaryCarbidopa/Levodopa39$27,832
Emgality PenGalcanezumab-Gnlm26$18,968
Rivastigmine140$17,663
VraylarCariprazine Hcl12$17,624
Memantine Hcl704$12,548
QuliptaAtogepant11$11,679
Levetiracetam267$10,636
BelsomraSuvorexant18$7,783
AdlarityDonepezil Hcl14$6,044
RivastigmineRivastigmine Tartrate107$4,978
Rufinamide19$4,823
Entacapone43$4,463
Donepezil Hcl410$3,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Vraylar, Qulipta$480$71,64552 claims
Amneal Pharmaceuticals LLCRytary$70$27,83239 claims
Corium, LLCAdlarity$87$6,04414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,246 neurology providers in Texas.

Other neurology in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →